Jardine Matheson acquires I-MED Radiology Network in $2.4bn healthcare imaging deal. The acquisition combines diagnostic imaging scale with growing AI capabilities as healthcare investors target data-rich clinical infrastructure. Jardine Matheson has agreed to acquire Australian diagnostic imaging provider I-MED Radiology Network for an enterprise value of A$3.4bn ($2.4bn), securing one of the largest radiology and teleradiology platforms in the Asia-Pacific region. The deal includes I-MED's minority stake in Harrison.ai, an artificial intelligence company developing radiology tools for CT brain and chest imaging, adding an AI component to an already significant healthcare infrastructure acquisition. A strategic bet on diagnostic infrastructure. I-MED operates 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually through a network of over 500 radiologists. Its services span MRI, CT, PET, nuclear medicine, ultrasound, and X-ray imaging, providing coverage across both metropolitan and regional healthcare markets. Alongside its physical clinic footprint, I-MED has built a substantial teleradiology operation, delivering remote image interpretation services across Australia, New Zealand, and the United States. This combination of physical infrastructure, specialist workforce, and digital reporting capability makes I-MED one of the most comprehensive imaging platforms in the region. Why Harrison.ai matters. While the acquisition is primarily focused on I-MED's diagnostic imaging operations, the inclusion of its stake in Harrison.ai is strategically significant. Harrison.ai develops artificial intelligence solutions designed to support radiologists in interpreting medical imaging, including CT brain and chest scans. As imaging volumes continue to rise globally and radiologist shortages persist across multiple healthcare systems, AI-assisted diagnostics are increasingly viewed as a critical productivity and workflow enhancement tool. The transaction therefore provides Jardine Matheson with exposure not only to diagnostic imaging demand but also to one of healthcare's fastest-growing technology categories. Why this deal matters now. The acquisition reflects growing investor interest in healthcare infrastructure assets that sit at the intersection of service delivery, clinical data generation, and artificial intelligence. Diagnostic imaging occupies a particularly valuable position within healthcare because it combines: * Recurring patient demand * Large-scale clinical data generation * Increasing AI integration opportunities * Essential diagnostic workflows As healthcare systems seek to improve efficiency and address workforce shortages, imaging networks are becoming increasingly attractive strategic assets. The inclusion of Harrison.ai further reinforces the growing convergence between healthcare services and AI-enabled clinical decision support. What this means for the industry. The Jardine Matheson-I-MED transaction highlights several major trends shaping healthcare investment: * Diagnostic imaging is emerging as a high-value healthcare infrastructure asset class * AI is increasingly becoming embedded within clinical workflows rather than existing as a standalone technology category * Investors are targeting businesses that combine service delivery with proprietary healthcare data generation * Teleradiology continues to expand as healthcare systems seek greater workforce flexibility and coverage The deal also demonstrates how healthcare investors are increasingly seeking assets that provide both operational scale today and technology-driven growth opportunities tomorrow. Summary. Jardine Matheson's $2.4bn acquisition of I-MED Radiology Network represents a major investment in healthcare infrastructure, combining one of Australasia's largest diagnostic imaging providers with exposure to emerging AI-powered radiology technologies. As healthcare increasingly converges with data, diagnostics, and artificial intelligence, platforms capable of generating, interpreting, and scaling clinical insight are becoming some of the most strategically valuable assets in the sector. Discover how nuaxia can support your next medical education initiative:

Harrison.ai has received FDA 510(k) clearance for acute infarct triage on non-contrast CT brain scans, becoming the first AI to achieve this clearance. The technology triages ischemic strokes across six vascular territories on initial CT scans, rather than later CT angiography scans used by existing stroke AI. The system achieved up to 89.2% sensitivity on thin slices and 85.7% on thick slices, outperforming existing large vessel occlusion devices that showed 63.5% sensitivity. Harrison.ai now offers eight FDA-cleared findings on non-contrast CT brain, the most comprehensive critical exam coverage of any AI triage platform. The company's solutions are deployed at over 1,000 customer sites globally, including 40 NHS Trusts, and have impacted more than seven million patients.